In a fresh blow, Bio­gen los­es a big court fight with My­lan over its block­buster Tec­fidera patent

The rough road Bio­gen has been trav­el­ing dur­ing the first half of 2020 just got con­sid­er­ably more bumpy.

A fed­er­al judge has ruled that Bio­gen’s cru­cial ‘514 patent is in­valid, leav­ing My­lan open to field­ing a gener­ic that would eat in­to block­buster rev­enue that has fu­eled the com­pa­ny for years.

“My­lan has es­tab­lished by clear and con­vinc­ing ev­i­dence that the as­sert­ed claims of the ’514 Patent are in­valid for lack of writ­ten de­scrip­tion,” ruled US Dis­trict Judge Irene Kee­ley.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER